Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?

van den Hoogen, Lotus LSmits, Gabyvan Hagen, Cheyenne C EWong, DeniseVos, Eric R Avan Boven, Michielde Melker, Hester Evan Vliet, JeffreyKuijer, MarjanWoudstra, LindeWijmenga-Monsuur, Alienke JGeurtsvanKessel, Corine HStoof, Susanne PReukers, DaphneWijsman, Lisa AMeijer, AdamReusken, Chantal B E MRots, Nynke Yvan der Klis, Fiona R Mvan Binnendijk, Robert Sden Hartog, Gerco2022-03-212022-03-212022-03-093528798610.1016/j.vaccine.2022.03.009http://hdl.handle.net/10029/625628enCopyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.COVID-19Multiplex immunoassayNucleoproteinSARS-CoV-2Serosurveillanceimmunoglobulin GSeropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?Article1873-2518Vaccine 2022; 40(15):2251-7